Thank you. There is an important point I would like to share with the committee.
There are two sides to the word "label", and it's a bit confusing. I myself was confused occasionally in the beginning.
The word “label” we often think of as the label on the bottle, which is the issue you referred to in terms of Sandoz. But the label we are talking about is a much more complex document, which is often posted on the web. It is the longer piece.
When we talk about simplifying the label, it's because we actually think physicians and Canadians need simpler language in the description of how to take the medication, what the contraindications are, what signs to look for, and the possible side effects. That is considered the label, and we think it's very important. That's why we're putting a great deal of emphasis on simplifying that information.
The actual issue we had with Sandoz—with one shipment having mislabelled vials in it—was very specific. It was a problem that was caught. There was a very significant effort, working with the company, to ensure that this was not something that actually reached Canadians or caused them any difficulty.
I would want to reassure the committee and the members that the label simplification we are talking about is so that consumers and practitioners have better information. It should not be linked in any way to the mislabelling problem that occurred at Sandoz.